Document:

Exhibit 4.4

 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)
OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED. 

 

SERIES D WARRANT TO PURCHASE ORDINARY SHARES
OF SAFE-T GROUP LTD.

 

	
    Warrant Shares: 370,370
	                   Warrant Issue Date: August __, 2022

 

THIS SERIES
D WARRANT (the “Warrant”) certifies that, effective as of the Warrant Issue Date (as defined above), Mr. Barak Avitbul
(the “Holder”) is entitled, on the terms set forth below, to purchase from Safe-T Group Ltd., a company incorporated
under the laws of the State of Israel (the “Company”), the Warrant Shares (as defined below), in accordance with the
terms hereof, at a purchase price per Warrant Share equal to the Series D Exercise Price (as defined below).

 

This Warrant is issued pursuant to the terms of
that certain agreement between the Company and ORB Spring Ltd., dated August 8, 2022 (the “Agreement”). In any conflict
between the provisions of this Warrant and the provisions of the Agreement, the provisions of the Agreement shall prevail. Any capitalized
term not specifically defined herein shall have such meaning as is ascribed to it in the Agreement.

 

		1.	Warrant Shares. Subject to the terms and conditions hereinafter set forth, the Holder is entitled
to subscribe for and purchase from the Company, during the exercise periods and subject to the vesting schedule set forth in Section ‎4
below, up to 370,370 fully paid and non-assessable Ordinary Shares of the Company (the “Warrant Shares”). The number
of the Warrant Shares issuable hereunder may be adjusted from time to time in accordance with the provisions of Section ‎8 below.

 

		2.	Exercise Price. The exercise price for each Warrant Share purchasable under this Warrant shall
be US$1.35 (the “Series D Exercise Price”).

 

		3.	Legend. Each certificate for
the Warrant Shares purchased under this Warrant shall bear a legend as follows unless such Warrant Shares have been registered under the
Securities Act of 1933, as amended:

 

The securities represented by this
certificate have not been registered under the Securities Act of 1933, as amended (the “Act”), or applicable state law. Neither
the securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant to an effective registration
statement under the Act, or pursuant to an exemption from registration under the Act and applicable state law which, in the opinion of
counsel to Safe-T Group Ltd., is available.

 

		4.	Exercise Period; Vesting.

 

		4.1.	185,185 Series D Warrants to purchase up to 185,185 Warrant Shares (50% of Series D Warrants) shall vest
on March 1, 2023 (the “Second Vesting Date”) and be exercisable as of the Second Vesting Date and for three (3) years
thereafter, subject to Section ‎4.3 below; provided, however, that the Warrants under this Section ‎4.1 shall expire on the Second
Vesting Date in the event the Milestone is not met, and the Partner has notified the Company on its decision to rescind the remaining
balance of the Facility;

 

    1

     

    

 

		4.2.	185,185 Series D Warrants to purchase up to 185,185 Warrant Shares (50% of Series D Warrants) shall vest
on September 1, 2023 (the “Third Vesting Date”) and be exercisable as of the Third Vesting Date and for three (3) years
thereafter, subject to Section ‎‎4.3 below; provided, however, that the Warrants under this Section ‎4.2 shall expire on the
Third Vesting Date in the event the Milestone is not met, and the Partner has notified the Company on its decision to rescind the remaining
balance of the Facility; and further provided, that the Warrants under this Section ‎‎4.2 shall expire on the Third Vesting Date
pro rata to the amounts of Tranches 3-8 which shall have not been actually withdrawn by the Company. By way of illustration only, (a)
if the Company, at its sole discretion, withdraws US$0.5 million out of US$2 million of Tranches 3-8 available under the Agreement, than
138,889 Series D Warrants to purchase up to 138,889 Warrant Shares [75% of Series D Warrants under this Section ‎4.2] shall expire
on the Third Vesting Date; and (b) if the Company, at its sole discretion, withdraws US$2 million out of US$2 million of Tranches 3-8
available under the Agreement, than none of Series D Warrants under this Section ‎4.2 shall expire on the Third Vesting Date;

 

		4.3.	Notwithstanding the above, if at any time from and after the date of issuance of the Warrants hereof,
the closing price of the Company’s Ordinary Shares on the TASE (or other stock exchange or market on which the Ordinary Shares are
then listed or quoted, including by means of ADSs, as defined below) equals or exceeds US$2.025 [1.5 (one point five) of Series D Exercise
Price per share], adjusted, if applicable, for the Company’s capital events, such as stock splits, etc., for three (3) consecutive trading
days (the “Mandatory Exercise Measuring Period”), then the Company shall have the right to require the Holder and/or
any of his Transferees, to exercise all or any portion of Series D Warrants, still unexercised (and in such event vesting of any such
unexercised Series D Warrants required to be exercised shall be accelerated and all of them shall vest immediately), for a cash exercise,
as designated in the Mandatory Exercise Notice on the Mandatory Exercise Date (each as defined below) into fully paid, validly issued
and nonassessable Ordinary Shares, at the Series D Exercise Price (the “Mandatory Exercise”). The Company may exercise
its right to require exercise under this Section ‎4.3 by delivering within not more than five (5) trading days following the end of
such Mandatory Exercise Measuring Period a written notice thereof to the Holder (which notice for the purposes hereof shall also be deemed
a notice to his Transferees (the “Mandatory Exercise Notice” and the date that Holder received such notice is referred
to as the “Mandatory Exercise Notice Date”). The Mandatory Exercise Notice shall be irrevocable. The Mandatory Exercise
Notice shall state (i) the trading day on which the Mandatory Exercise shall occur, which shall be the second trading day following the
Mandatory Exercise Notice Date (the “Mandatory Exercise Date”) and (ii) the aggregate number of Warrants which the Company
has elected to be subject to such Mandatory Exercise (the “Mandatory Exercise Warrants”) pursuant to this Section ‎4.3.
If the Holder or any of his Transferees then holding the Warrants, fails to provide the Company on the Mandatory Exercise Date or within
five (5) business days thereafter, with the aggregate exercise price of the Mandatory Exercise Warrants or any part thereof, at the end
of such period any nonpaid Mandatory Exercise Warrants shall automatically terminate and become null and void.

 

		4.4.	Notwithstanding the above, this Warrant may not be exercised on the Record
Date (as such term is defined under the TASE rules and regulations) of: (i) a distribution of bonus shares; (ii) a rights offer; (iii)
any distribution of dividends; (iv) a consolidation of the share capital of the Company; (v) a share split; or (vi) a reduction of the
share capital of the Company (each of the above: a “Corporate Event”). In addition, if the Ex-Date (as such term is
defined under the TASE rules and regulations) for a Corporate Event occurs before the Record Date for such Corporate Event, then the Warrant
may not be exercised on the said Ex-Date.

 

    2

     

    

 

		5.	Manner of Exercise.

 

		5.1.	The Warrant may be exercised by the delivery of the Warrant to the Company at its principal office, together
with a duly executed copy of the form of Notice of Exercise attached hereto as Exhibit A, to the chief financial officer
of the Company at its principal offices and the payment to the Company of an amount equal to the aggregate of the Series D Exercise Price
for all of the Warrant Shares being purchased, in immediately available cash funds.

 

		5.2.	Unless otherwise agreed in writing by the Parties, the closing of each such Exercise Notice shall occur
no later than three (3) TASE trading days after the date of delivery of such Exercise Notice (the “Warrant Closing Date”),
at which time Holder shall pay its Exercise Price to the Company by wire transfer and the Company shall issue the Warrant Shares and transfer
to its registration company (the “Registration Company”) all the documents and information required in order to deposit
the Warrant Shares in Holder’s account (which details shall be provided to the Company in the Exercise Notice) and shall cause the Registration
Company to register such deposit; if and when issued in accordance with the provisions hereof, the Warrant Shares shall be listed for
trading on the TASE and, subject to the provisions of Section 3.7 of the Agreement, on Nasdaq.

 

		5.3.	No fractional shares or scrip representing fractional shares shall be issued upon exercise of this Warrant.
As to any fraction of a Warrant Share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Series D Exercise Price or round up to the next whole share.

 

		6.	Issuance of Shares on Exercise. Following an exercise as provided in Section ‎‎5 above,
the Warrant Shares so purchased shall be issued and the Holder shall be deemed the record owner of such Warrant Shares, as of the close
of business on the date on which the last of the actions required to exercise the Warrant as provided in Section ‎5 above has been
completed.

 

		7.	Holder’s Rights as a Shareholder. The Holder shall not be entitled to any right as a shareholder
of the Company with respect to Warrant Shares until such time that it becomes a holder of Warrant Shares in accordance with Section ‎6
above. Upon becoming a holder of Warrant Shares, such shares shall entitle the Holder to all rights attached to the shares of the same
class under the Company’s articles of association (the “Articles”) then in effect.

 

		8.	Adjustments

 

The Series D Exercise
Price and the number of Warrant Shares purchasable hereunder are subject to adjustment from time to time, as follows:

 

		8.1.	If the Company at any time, while any of the Warrants are exercisable and outstanding, subdivides its
Ordinary Shares, the number of Warrant Shares issuable upon exercise of the Warrants shall be proportionately increased and, for the avoidance
of any doubt, the Series D Exercise Price per Warrant Share shall be proportionally reduced.

 

		8.2.	If the Company at any time, while any of the Warrants are exercisable and outstanding, combines its Ordinary
Shares, the number of Warrant Shares issuable upon the exercise of the Warrants shall be proportionately decreased and, for the avoidance
of any doubt, the Series D Exercise Price per Warrant Share shall be proportionally increased.

 

		8.3.	If the Company at any time, while any of the Warrants are exercisable and outstanding, pays a dividend
with respect to the Ordinary Shares, then the Series D Exercise Price shall be adjusted, from and after the date of determination of shareholders
entitled to receive such dividend or distribution (the “Record Date”), to such price that equals the product of the
Series D Exercise Price in effect immediately prior to the Record Date multiplied by a fraction (X) the numerator of which shall be the
opening price of the Ordinary Shares as published by the TASE on the “Ex-Dividend” date, and (Y) the denominator of which
shall be the closing price of the Ordinary Shares as published by the TASE on the last trading day immediately prior to the relevant “Ex-Dividend”
date. Such adjustment shall be subject to the receipt of any tax ruling or approval required under applicable law.

 

    3

     

    

 

		8.4.	In the event that the Company at any time, while any of the Warrants are exercisable and outstanding,
makes or fixes a record date for the determination of holders of shares entitled to receive bonus shares, then the number of Warrant Shares
exercisable upon exercise of the Warrants then outstanding shall be increased by a number of Warrant Shares equal to the number of shares
that the Holder would have been entitled to receive in respect of the Warrant Shares for which the Warrants could have been exercised
immediately prior to the ex-bonus shares date.

 

		8.5.	In the event that the Company at any time, while any of the Warrants are exercisable and outstanding,
makes or fixes a record date for the determination of holders of shares entitled to receive rights to purchase shares of the Company upon
any rights offering by the Company, then the number of Warrant Shares exercisable upon the exercise of the Warrants then outstanding shall
be increased to reflect the bonus component in the rights offering, being expressed as a fraction, the numerator of which shall be the
closing price of the Ordinary Shares as published by TASE on the last trading day immediately prior to the ex-rights date and the denominator
of which shall be the ex-rights price per share as shall be published by TASE.

 

		8.6.	If the Company, at any time, while any of the Warrants are exercisable and outstanding, distributes to
holders of Ordinary Shares as a dividend any asset other than cash or Company’s securities (in each case, “Distributed Property”),
then provision shall be made so that upon exercise of the Warrants, the Company will deliver to the Holder with respect to Holder’s warrants
then outstanding the Distributed Property that such holder would have been entitled to receive in respect of the Warrant Shares for which
the Holder’s outstanding warrants could have been exercised immediately prior to the record date of such distribution. 

 

		8.7.	If a Merger Event (as defined below) occurs at any time while the Warrants are exercisable and outstanding,
then lawful provision shall be made so that Holder shall thereafter be entitled to receive, upon exercise of the Warrants, the number
of Ordinary Shares or other securities or property of the successor corporation resulting from such Merger Event that would have been
issuable if Holder had exercised the Warrants immediately prior to the Merger Event. In any such case, the Company shall take all action,
including any adjustment (as determined in good faith by the Company’s Board of Directors with respect to all outstanding options and
warrants issued by the Company), to protect all the rights and interests of the Holder after the Merger Event such that all rights and
interests of the Holder in this Agreement (including adjustments of the Exercise Price and/or number of Ordinary Shares purchasable) shall
be applicable in their entirety. For the purposes hereof “Merger Event” means a merger or consolidation involving the Company
in which the Company is not the surviving entity, or in which the outstanding Ordinary Shares of the Company are otherwise converted into
or exchanged for shares of capital of another entity.

 

    4

     

    

 

		9.	Representations and Warranties of the Company

 

The Company represents and
warrants to Holder as follows:

 

		9.1.	This Warrant has been duly authorized and executed by the Company and is a valid and binding obligation
of the Company enforceable in accordance with its terms. The Warrant Shares are duly authorized and reserved for issuance by the Company
and, when issued in accordance with the terms hereof, will be (i) duly authorized, validly issued, fully paid, non-assessable, (ii) issued
in compliance with all applicable laws, including Israeli Securities Law and the Act, (iii) free of any rights of first refusal, co-sale
rights, preemptive rights or any other applicable subscription or participation rights and (iv) free and clear of any liens, claims, encumbrances
or third party rights of any kind, subject to any lock-up requirements as prescribed by law and referenced in Sections 3.5 and 3.6 of
the Agreement (of which the Holder is aware). Holder acknowledges that in making the foregoing representation the Company is relying upon
Holder’s representations in the Agreement, including without limitation in Section 3.8 of the Agreement and the certificate provided
thereunder, and Holder hereby represents and warrants to the Company that such representations and warranties are accurate as of the date
hereof.

 

		9.2.	The execution and delivery of this Warrant are not, and the issuance of the Warrant Shares upon exercise
of this Warrant in accordance with the terms hereof will not be, inconsistent with the Articles and any other Company’s governing documents,
do not and will not contravene any law, regulation or judgment applicable to the Company, and do not and will not conflict with or contravene
any provision of, or constitute a default under, any legal instrument of which the Company is a party or by which it is bound.

 

		10.	Transferability. Series D Warrants shall not be transferrable, save to transfer to the Transferees.
Any transfer to a Transferee hereunder shall be conducted by using the Form of Transfer, substantially in the form of Exhibit B
hereto.

 

		11.	Saturdays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a business day, then such action may be taken or such right may be exercised on the
next succeeding business day.

 

		12.	Entire Agreement, Amendments. This Warrant, the Agreement and any other documents delivered pursuant
hereto or thereto, set forth the entire understanding of the parties with respect to the subject matter hereof. No modification or amendment
of this Warrant will be valid unless executed in writing by the Company and the Holder.

 

		13.	Notices. All notices and other communications given or made pursuant to this Warrant shall be in
writing and shall be given and deemed delivered as provided in Section 13 to the Agreement.

 

		14.	Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only
and are not to be considered in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits
shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto.

 

		15.	Law; Jurisdiction. Provisions of Section 10 of the Agreement shall apply with regard to the governing
law and jurisdiction.

 

		16.	Counterparts. This Warrant may be executed in any number of counterparts, each of which shall be
deemed an original and enforceable against the parties actually executing such counterpart, and all of which together shall constitute
one and the same instrument.

 

[signature page follows]

 

    5

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by a duly authorized officer.

 

SAFE-T
GROUP LTD.

 

	_______________________________________	

		By:	Shachar Daniel, Chief Executive Officer

Shai Avnit, Chief Financial Officer

 

AGREED AND ACCEPTED:

 

_________________________

Barak Avitbul

 

    6

     

    

 

EXHIBIT A

NOTICE OF EXERCISE

 

To: SAFE-T LTD.

 

Attn: Chief Financial Officer

 

		1.	The undersigned hereby elects to purchase [FILL IN NUMBER OF SHARES] ____________ shares of Ordinary
Shares of the share capital of Safe-T Ltd. pursuant to the terms of the attached Series D Warrant (the “Warrant”),
and tenders herewith payment in full for the purchase price of the shares being purchased.

 

		2.	Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned,
and record same in the Company’s internal share registry.

 

		3.	The undersigned hereby represents and warrants that the aforesaid Warrant Shares are being acquired for
the account of the undersigned for investment and not with a view to, or for resale, in connection with the distribution thereof, and
that the undersigned has no present intention of distributing or reselling such shares. The undersigned further represents and warrants
that the representations of Mr. Barak Avitbul contained in Section 3.8 of the Agreement between the Company and ORB Spring Ltd. and acknowledged
by Mr. Avitbul, dated July __, 2022, remain accurate in all respects as of the date hereof (it being understood that if the undersigned
is a Transferee of the Warrant from Mr. Avitbul, such representations are being made by the undersigned as if it were a party to such
Agreement).

 

	 	By:	
	 	Name:	
	 	Title:	
	 	Address:	
	 	Date:	

 

    7

     

    

 

EXHIBIT B

FORM OF TRANSFER

(To be signed only upon transfer of Warrant)

 

FOR VALUE RECEIVED, the undersigned (the “Transferor”)
hereby sells, assigns and transfers unto ______________________________________________, being Transferee, (the “Transferee”)
the Warrant to purchase _____________ Warrant Shares in an aggregate exercise price of US$ _________ and appoints ______________, as Attorney-in-Fact
to transfer said Warrant on the books of Safe-T Group Ltd., with full power of substitution in the premises. The Transferor further represents
that the transfer is made in accordance with the terms of the Warrant.

 

Dated:                                             

                                                        

By: Barak Avitbul

 

and the undersigned Transferee hereby agrees to
the transfer and agrees to be bound by the terms and conditions of the Warrant and represents and warrants that the representations contained
in Section 3.8 of the Agreement between the Company and ORB Spring Ltd. (“ORB”), dated July __, 2022, remain accurate in all
respects as of the date hereof (it being understood that such representations are being made by the undersigned as if it were a party
to such Agreement).

 

Dated: __________________

 

By: 

Name: 

 

 

    8Exhibit 10.1

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT SAFE-T GROUP
LTD. TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DENOTED IN BRACKETS THROUGHOUT THIS EXHIBIT.

 

AGREEMENT

 

This
Agreement (the “Agreement”) is made and entered into on August 8, 2022, by and between Safe-T Group Ltd., an Israeli
corporation, having it principal place of business at 8 Abba Evan Ave., Herzliya 4672526, Israel (“Company”), and
ORB Spring Ltd., an Israeli corporation, having it principal place of business at 47 King David Blvd., Tel-Aviv 6423715 Israel (“Partner”). Each
of the Company and Partner may also hereinafter be referred to as a “Party”, or collectively as the “Parties”.

 

RECITALS

 

WHEREAS,
Partner seeks to expand its investment portfolio into commerce marketing by extending financing to support the generation of revenue
from the sale of certain commerce marketing products;

 

WHEREAS,
Company, through its wholly owned subsidiary, CyberKick Ltd. (“Subsidiary”), seeks to monetize such financing for
certain operating expenses and costs in connection with acquisition of customers for certain of its commerce marketing Products (as defined
herein), and

 

NOW, THEREFORE,
in consideration of the mutual covenants and promises contained herein, each of Partner and Company, intending to be legally bound, hereby
agrees as follow:

 

AGREEMENTS

 

		1.	Facility. 

 

		1.1.	Subject
                                            to the terms and conditions set forth herein, Partner agrees to extend to the Company
                                            an aggregate amount of up to $4,000,000.00 (the “Facility”) only to finance
                                            certain operating expenses and costs in connection with acquisition of customers and
                                            thus facilitate a transaction or series of transactions whereby the Subsidiary sells new
                                            subscriptions of its products and/or services (the “Product/s”) to third
                                            parties customers (the “Customer/s”), resulting in revenues to the Subsidiary
                                            (the “Customer Acquisition”). As of date hereof and up to the End Date
                                            (as defined in Section ‎1.2 below) the Company shall inform the Partner in writing, upon
                                            the Partner’s request, on the Customer Acquisition effected through tools and channels
                                            which has not been used for such purpose up to the date hereof. When used herein,
                                            the term “Product” is limited only to the products listed in Schedule 1
                                            attached hereto, which list may be updated from time to time by mutual written agreement
                                            between the Parties, including with respect to the terms of Net Eligible Revenue (as defined
                                            herein) share for such products that may be added from time to time.

 

    1

     

    

 

		1.2.	The
                                            Facility shall be made available to the Company in tranches over a period ending on July
                                            15, 2023 (the “End Date”), in accordance with the timetable and in amounts
                                            set forth in Schedule 1.2 attached hereto and subject to Section ‎1.4 below (each,
                                            a “Tranche”). The Company shall repay the Facility to the Partner subject
                                            to and in accordance with the provisions of Section 2 below.

 

		1.3.	Except
                                            of the first two Tranches, for each of the Tranches, the Company may elect, at its sole discretion
                                            and based on the Company’s requirements, to draw less than the amount designated for
                                            such Tranche, and defer the unused balance to the next Tranches, provided that in no event
                                            the unused balance aggregates to $[**] or more. Upon the date on which the unused balance
                                            exceeds $[**] or, unless the Parties agree in writing to extend the term of the Facility
                                            beyond the End Date, upon the End Date, any unused balance which is not deferred pursuant
                                            to the provision above, shall be deemed as unused and irrevocably waived by the Company and
                                            the Partner shall have no obligation to provide the waived amount to the Company, and the
                                            Company shall have no obligations toward the Partner in connection with such waived amount.
                                            At least 10 business days in advance of the due date for payment of each Tranche, the Company
                                            shall deliver to Partner a written notice confirming the actual amount it wishes to draw,
                                            which amount shall not exceed the amount designated for such Tranche except to the extent
                                            that unused balance from previous Tranche is deferred to the following Tranche(s) as set
                                            forth herein. Following receipt of such notice and subject to transfer of such amount by
                                            Partner, the respective payment by Partner shall be deemed as the “Actual Tranche”
                                            and in aggregate all Actual Tranches shall be deemed the “Principal Facility”.

 

		1.4.	Notwithstanding
                                            any other provision of this Agreement, including the Tranches timetable set forth in Schedule
                                            1.2, the Partner shall
                                            have the right, at its sole discretion, to unilaterally rescind the remaining balance of
                                            the Facility if on February 15, 2023 the aggregate payment amounts, due and payable to the
                                            Partner by that date in accordance with Section ‎2 below with respect to the first two
                                            Actual Tranches (assuming each of them is in amount set forth in Schedule ‎1.2),
                                            whether actually received or yet received by the Partner from the Company, fall short of
                                            $[**]
                                            (“Milestone”).
                                            In the event
                                            the Milestone is not met, the Partner shall notify the Company in writing not later than
                                            February 20, 2023 on its decision whether to rescind
                                            or provide the remaining balance of the Facility.

 

		2.	Facility
                                            Return.

 

The
Company shall pay the Principal Facility and additional payments to the Partner, out of Net Eligible Revenues (as defined in Section
‎2.4 below) as follows:

 

		2.1.	Unless
                                            an Actual Tranche is repaid in full, the Partner shall be entitled to all of the Net Eligible
                                            Revenues generated or pro rata share thereof, in accordance with the provisions of Section
                                            ‎2.2 below. Once an Actual Tranche has been repaid
                                            in full and until the date set forth in Schedule ‎1.2 for each
                                            such Actual Tranche, Company shall pay Partner an amount equal to 50% of Net Eligible Revenues
                                            received with respect to such Actual Tranche (or less, subject to and in accordance with
                                            the provisions of Section ‎2.2) and retain
                                            the remainder of such Net Eligible Revenues. Upon reaching such lapse date with respect to
                                            the last Actual Tranche, the Company’s obligation to make any further payments
                                            to Partner shall terminate, and thereafter, Company shall retain 100% of all revenues, including
                                            the Net Eligible Revenue.

 

    2

     

    

 

		2.2.	The
                                            repayment amount due by Company to Partner and all other measurements herein shall be
                                            calculated separately with respect to each Actual Tranche, and shall be repaid out
                                            of the Net Eligible Revenues (as defined below) generated by those Customers acquired utilizing
                                            amounts equal to such Actual Tranche or Actual Tranches, as set forth in Schedule ‎1.2;
                                            provided that if any additional budget, other than the Principal Facility, is utilized for
                                            acquisition of the Customers during the term of this Agreement, the Net Eligible Revenues
                                            assigned for payments to the Partner hereunder shall be calculated on pro rata basis. [**]

 

		2.3.	Notwithstanding
                                            any other provision herein, on the date set forth in Schedule ‎1.2 for each Actual
                                            Tranche (each “Measure Date”), the total repayment due to Partner shall
                                            constitute at least 100% of the respective Actual Tranche. If
                                            on each respective Measure Date, the aggregate Net Eligible Revenue (from the respective
                                            Customers) repayments paid by the Company and received by the Partner are less than
                                            the respective Actual Tranche, then Company
                                            shall complete payment to Partner by paying the balance between the aggregate Net
                                            Eligible Revenue paid to Partner and such Actual Tranche, within ten (10) business days following
                                            the respective Measure Date. The Company may elect, at its sole discretion, to pay
                                            any such difference to Partner in cash or by issuance of ordinary shares of the Company to
                                            Mr. Barak Avitbul, the controlling shareholder of the Partner, at a per share price equal
                                            to the average price of the Company’s shares on Tel Aviv Stock Exchange Ltd. (the “TASE”)
                                            for the thirty (30) trading days immediately prior to a Measure Date, which issuance shall
                                            be subject to receiving TASE approval for listing of such ordinary shares for trade on the
                                            TASE (the “TASE Approval”).

 

		2.4.	Net
                                            Eligible Revenues. For the purpose of this Agreement, “Net Eligible Revenues”
                                            shall mean revenues generated
                                            by and received from subscriptions for the Products
                                            by Customers that were purchased using amounts equal to each Actual
                                            Tranche during the periods set forth in Schedule ‎1.2, minus direct costs associated
                                            with agents’ commissions and/or other payments to third parties in connection with
                                            such revenues.

 

		2.5.	Payment
                                            and Reporting. The Net Eligible Revenue
                                            shall be calculated on a monthly basis, commencing the end of the last day of each month
                                            following each Actual Tranche. For each month for which Company has an obligation to
                                            make payment of Net Eligible Revenue or any
                                            part thereof, such payments shall be accompanied by a written report that specifies the Net
                                            Eligible Revenue for such month and the manner in which such Net Eligible Revenue is calculated.
                                            Company shall make respective payments to Partner within 10 business days after the end of
                                            the applicable month in which Net Eligible Revenues, from which such payments are derived,
                                            have been received.

 

		2.6.	Right
                                            to Audit. The
                                            Partner and its representatives shall have the right to conduct an audit of the relevant
                                            books, records and accounts related to the Net Eligible Revenues during normal business hours
                                            upon giving reasonable notice of their intent to conduct such an audit, solely to verify
                                            compliance with this Agreement. In the event of such audit, the Company shall comply with
                                            the reasonable requests of the Partner and its representatives and provide access to all
                                            books, records, and accounts reasonably necessary for such audit, including [**]
                                            account
                                            records. The audit shall be conducted at Partner’s expense, unless the audit reveals that
                                            the Company has understated the applicable Net Eligible Revenues amount by more than 5%,
                                            in which event the Company shall reimburse the Partner for such expenses. 

 

    3

     

    

 

		2.7.	For
                                            the avoidance of any doubt, the Parties hereby agree
                                            and acknowledge that any reference herein to acquisition of Customers by the Subsidiary,
                                            or revenues, including Net
                                            Eligible Revenues, accrued by the Subsidiary, is made solely
                                            for the purpose of calculating the amounts due and payable to the Partner hereunder and in
                                            any event no funds shall be paid by the Subsidiary to the Partner. 

 

		3.	Warrants
                                            to Purchase Company Ordinary Shares.

 

		3.1.	The
                                            Warrants. Within 7 days following the date on which the first Tranche shall have been
                                            received by the Company (the “Date of Issuance”), the Company shall issue
                                            to Mr. Barak Avitbul, the controlling shareholder of the Partner, warrants to purchase the
                                            Company’s ordinary shares, no par value (the “Warrants” and “Ordinary
                                            Shares”, respectively), as follows: (i) a warrant to purchase up to 2,068,966 Ordinary
                                            Shares of the Company exercisable at a price per share of US$0.725 (the “Series
                                            A Warrant” and the “Series A Exercise Price”, respectively;
                                            (ii) a warrant to purchase up to 344,828 Ordinary Shares of the Company exercisable at a
                                            price per share of US$1.45 (the “Series B Warrant” and the “Series
                                            B Exercise Price”, respectively; (iii) a warrant to purchase up to 2,222,222 Ordinary
                                            Shares of the Company exercisable at a price per share of US$0.675 (the “Series
                                            C Warrant” and the “Series C Exercise Price”, respectively);
                                            and (iv) a warrant to purchase up to 370,370 Ordinary Shares of the Company exercisable at
                                            a price per share of US$1.35 (the “Series D Warrant” and the “Series
                                            D Exercise Price”, respectively). None of the Warrants shall be transferrable,
                                            save to transfer to (i) the Permitted Transferees and (ii) transfer to any third party or
                                            parties (the “Third Parties”) of such amount of Warrants which constitutes
                                            up to 1,251,597 Warrants (25% of the Warrants issued to the Holder under the Agreement).
                                            For the purposes hereof “Permitted Transferees” shall mean any of (a)
                                            Barak’s spouse, children, parents or siblings (including any test; (b) trust created
                                            by Barak for the primary benefit of one or more of (i) Barak, (ii) Barak’s
                                            spouse, and (iii) Barak’s children, parents or siblings; (c) any legal entity
                                            controlled by Barak. For the purposes hereof, Permitted Transferees and Third Parties, shall
                                            collectively be referred to as “Transferees”.

 

		3.2.	The
                                            Warrants shall vest and be exercisable as follows:

 

		3.2.1.	50%
                                            of Series A and Series B Warrants shall be fully vested and immediately exercisable as of
                                            the Date of Issuance and prior to the expiration of three (3) years following the Date of
                                            Issuance, subject to Section ‎3.3 below;

 

		3.2.2.	50%
                                            of Series A and Series B Warrants shall vest on December 1, 2022 (the “First Vesting
                                            Date”) and be exercisable as of the First Vesting Date and prior to the expiration
                                            of three (3) years following the Date of Issuance, subject to Section ‎3.3 below; provided,
                                            however, that the Warrants under this Section ‎3.2.2 shall expire on the First Vesting
                                            Date in the event the Partner fails to provide the second Tranche in the amount and prior
                                            to or upon the date set forth in Schedule ‎1.2;

 

    4

     

    

 

		3.2.3.	50%
                                            of Series C and Series D Warrants shall vest on March 1, 2023 (the “Second Vesting
                                            Date”) and be exercisable as of the Second Vesting Date and for three (3) years
                                            thereafter, subject to Section ‎3.3 below; provided, however, that the Warrants under
                                            this Section ‎3.2.3 shall expire on the Second Vesting Date in the event the Milestone
                                            is not met, and the Partner has notified the Company on its decision to rescind
                                            the remaining balance of the Facility;

 

		3.2.4.	50%
                                            of Series C and Series D Warrants shall vest on September 1, 2023 (the “Third Vesting
                                            Date”) and be exercisable as of the Third Vesting Date and for three (3) years
                                            thereafter, subject to Section ‎3.3 below; provided, however, that the Warrants under
                                            this Section ‎3.2.4 shall expire on the Third Vesting Date in the event the Milestone
                                            is not met, and the Partner has notified the Company on its decision to rescind
                                            the remaining balance of the Facility; and further provided, that the Warrants under
                                            this Section ‎3.2.4 shall expire on the Third Vesting Date pro rata to the amounts of
                                            Tranches 3-8 which shall have not been actually withdrawn by the Company. By way of illustration
                                            only, (a) if the Company, at its sole discretion, withdraws US$0.5 million out of US$2 million
                                            of Tranches 3-8 available under this Agreement, than 75% of the Warrants under this Section
                                            ‎3.2.4 (i.e., 37.5% of the total amount of Series C Warrants and 37.5% of the total amount
                                            of Series D Warrants) shall expire on the Third Vesting Date; and (b) if the Company, at
                                            its sole discretion, withdraws US$2 million out of US$2 million of Tranches 3-8 available
                                            under this Agreement, than none of the Warrants under this Section ‎3.2.4 shall expire
                                            on the Third Vesting Date.

 

		3.3.	Mandatory
                                            Exercise of Warrants. If at any time from and after the date of issuance of the
                                            Warrants hereof, the closing price of the Company’s Ordinary Shares on the TASE (or
                                            other stock exchange or market on which the Ordinary Shares are then listed or quoted, including
                                            by means of ADSs, as defined below) equals or exceeds 1.5 (one point five) of Series A Exercise
                                            Price per share (with regard to Series A Warrants ), 1.5 (one point five) of Series B Exercise
                                            Price per share (with regard to Series B Warrants), 1.5 (one point five) of Series C Exercise
                                            Price per share (with regard to Series C Warrants) or 1.5 (one point five) of Series D Exercise
                                            Price per share (with regard to Series D Warrants) adjusted, if applicable, for the Company’s
                                            capital events, such as stock splits, etc., for three (3) consecutive trading days (the “Mandatory
                                            Exercise Measuring Period”), then the Company shall have the right to require Mr.
                                            Avitbul, and/or any of his Permitted Transferees, to exercise all or any portion of Series
                                            A Warrants, Series B Warrants, Series C Warrants or Series D Warrants, as the case may be,
                                            still unexercised (and in such event vesting of any such unexercised Warrants required to
                                            be exercised shall be accelerated and all of them shall vest immediately), for a cash exercise,
                                            as designated in the Mandatory Exercise Notice on the Mandatory Exercise Date (each as defined
                                            below) into fully paid, validly issued and nonassessable Ordinary Shares, at the Series A,
                                            Series B, Series C or Series D Exercise Price (as the case may be) (the “Mandatory
                                            Exercise”). The Company may exercise its right to require exercise under this Section
                                            ‎3.3 by delivering within not more than five (5) trading days following the end of such
                                            Mandatory Exercise Measuring Period a written notice thereof to Mr. Avitbul (which notice
                                            for the purposes hereof shall also be deemed a notice to his Permitted Transferees (the “Mandatory
                                            Exercise Notice” and the date that Mr. Avitbul received such notice is referred
                                            to as the “Mandatory Exercise Notice Date”). The Mandatory Exercise Notice
                                            shall be irrevocable. The Mandatory Exercise Notice shall state (i) the trading day on which
                                            the Mandatory Exercise shall occur, which shall be the second trading day following the Mandatory
                                            Exercise Notice Date (the “Mandatory Exercise Date”) and (ii) the aggregate
                                            number of Warrants which the Company has elected to be subject to such Mandatory Exercise
                                            (the “Mandatory Exercise Warrants”) pursuant to this Section ‎3.3.
                                            If the Mr. Avitbul or any of his Permitted Transferees then holding the Warrants, fails to
                                            provide the Company on the Mandatory Exercise Date or within five (5) business days thereafter,
                                            with the aggregate exercise price of the Mandatory Exercise Warrants or any part thereof,
                                            at the end of such period any nonpaid Mandatory Exercise Warrants shall automatically terminate
                                            and become null and void.

 

    5

     

    

 

		3.4.	The
                                            Series A Warrants, Series B Warrants, Series C Warrants and Series D Warrants shall be substantially
                                            in the forms attached hereto as Schedule ‎3.4A, Schedule ‎3.4B, Schedule
                                            ‎3.4C and Schedule ‎3.4D, respectively.

 

		3.5.	Mr.
                                            Avitbul acknowledges and is aware that issuance of the Warrants and the listing of Ordinary
                                            Shares underlying such warrants (the “Warrant Shares”)
                                            on trade with the TASE will be subject to TASE Approval and that such Warrant Shares shall
                                            be subject to restrictions on resale set forth in Section 15C of the Israeli Securities Law
                                            and the Securities Regulations (Details Regarding Sections 15A to 15C of the Law), 2000 (collectively,
                                            the “Securities Law”). Mr. Avitbul hereby acknowledges that the Company
                                            accepts no responsibility for his compliance with lock-up period requirements. Mr. Avitbul
                                            understands and acknowledges that the Ordinary Shares (whether Warrant Shares or Ordinary
                                            Shares issued in accordance with Section ‎2.3 above), if and when converted into American
                                            Depositary Shares (“ADS”), or if otherwise disposed in the United States
                                            or to a U.S. person, may only be disposed of in compliance with respective U.S. state and
                                            U.S. federal securities laws.

 

		3.6.	In
                                            connection with any transfer of ADSs other than pursuant to an effective registration statement,
                                            the Company may require Mr. Avitbul to provide to the Company an opinion of counsel selected
                                            by Mr. Avitbul and reasonably acceptable to the Company, the form and substance of which
                                            opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
                                            does not require registration of such transferred ADS under the Securities Act of 1933, as
                                            amended (the “Securities Act”).

 

		3.7.	Without
                                            derogating from the provisions of Sections 3.3 and 3.4 herein, (i) within 7 days following
                                            the date hereof, the Company shall submit an application with TASE for the TASE Approval
                                            and shall use best efforts to obtain the Tase Approval as promptly as practicable; and (ii)
                                            within 60 days following the Date of Issuance of the Warrants, the Company shall file with
                                            the U.S. Securities Exchange Commission (the “SEC”) a registration statement
                                            with respect to the resale of the maximum amount ADSs that may be issuable upon the conversion
                                            of Warrant Shares and shall use best efforts to have such registration statement declared
                                            effective as promptly as practicable. The Company shall use best efforts to keep the registration
                                            statement continuously effective until the earlier of (i) the date after which all of the
                                            securities to be registered thereunder have been sold, or (ii) four (4) years following the
                                            Date of Issuance. Any costs arising out of or in connection with the foregoing shall be borne
                                            by the Company.

 

		3.8.	In
                                            connection with the issuance of the Warrants, Mr. Avitbul represents that his is a non-U.S.
                                            Person as defined under Regulation S promulgated under the Securities Act. Mr. Avitbul further
                                            represents that he (i) is not receiving the Warrants for the account or benefit of any U.S.
                                            Person, (ii) is not, at the time of execution of this Agreement, and will not be, at the
                                            time of the issuance of the Company’s ADSs, in the United States, (iii) is not a “distributor”
                                            (as defined in Regulation S promulgated under the Act), (iv) is an “accredited investor”
                                            as such term is defined in Rule 501 of Regulation D promulgated by the SEC under the Securities
                                            Act; (v) is able, by reason of his business and financial experience, to protect his own
                                            interests in connection with the issuance of Warrants; and (vi) is able to afford the entire
                                            loss of his investment in the Warrant Shares. For the purpose of filing the registration
                                            statement pursuant to Section ‎3.7 above, Mr. Avitbul shall execute and deliver to the
                                            Company a certification in the form attached as Schedule ‎3.8 hereto.

 

    6

     

    

 

		3.9.	The
                                            Partner and Mr. Barak Avitbul shall deliver and/or procure the delivery to the Company of
                                            any information or document with respect to them and/or the transactions contemplated by
                                            this Agreement, which is required, if so required, under any applicable laws and regulations
                                            to be filed by the Company with the Israel Securities Authority, the TASE and/or the SEC.

 

		3.10.	If
                                            and when the Warrant Shares are issued in accordance with the provisions hereof, the Company
                                            shall deliver to its registration company, and to the TASE and the Nasdaq (if required),
                                            with a copy to Mr. Avitbul, all the documents and information needed in order to deposit
                                            the Warrant Shares in the bank account(s) (which details shall be provided to the Company
                                            prior to or on the date the Warrants underlying the Warrants Shares are so exercised); if
                                            and when issued in accordance with the provisions hereof, the Warrant Shares shall be listed
                                            for trading on the TASE.

 

		4.	Right
                                            of Participation. 

 

		4.1.	If
                                            at any time from the date of the first Actual Tranche and until such date that at least seventy
                                            percent (70%) of the Principal Facility is repaid to Partner, the Company issues securities
                                            of the Company for cash consideration (the “Equity Securities” and “Equity
                                            Financing”, respectively) then Partner and/or its assignees (meaning any person
                                            or entity that controls, is controlled by or is under common control with the Partner) shall
                                            have the right to purchase up to the Partner’s Pro Rata Share (as of the date
                                            of Equity Financing) of the securities issued in such Equity Financing, on the same
                                            terms and conditions as are offered to other purchasers in such Equity Financing. Partner’s
                                            “Pro Rata Share” of any issuance or sale of Equity Securities means, on any issuance
                                            date for Equity Securities, the number of such Equity Securities equal to the product of
                                            (i) the total number of new Equity Securities to be issued by the Company on such date and
                                            (ii) the fraction determined by dividing (x) the number of Ordinary Shares acquirable upon
                                            complete exercise of all warrants issued to Mr. Avitbul by Company hereunder (without regard
                                            to any limitations on exercise thereof) immediately prior to the closing date of the Equity
                                            Financing by (y) the total number of Ordinary Shares issued and outstanding immediately prior
                                            to such issuance plus the number of Ordinary Shares set forth in (x) above (the “Right
                                            of Participation”). The Partner may, at its sole discretion, apply the Principal
                                            Facility for purchase of the Pro Rata Share securities, on first-in first-out basis (i.e.,
                                            first applying the earlier Actual Tranches for such purpose), in which event the Company’s
                                            obligations hereunder with regard to the Principal Facility amounts so applied shall terminate
                                            upon issuance of the Pro Rata Share securities.

 

    7

     

    

 

		4.2.	The
                                            Company shall notify Partner in writing by email addressed to Partner’s Representative
                                            not less than three (3) business days prior to the proposed closing date of the Equity Financing
                                            (which date shall be specified in such notice), which notice shall be accompanied by all
                                            agreements and other documents then in place to be delivered to or signed by other prospective
                                            investors in the Equity Financing, and if Partner wishes to participate in the Equity Financing,
                                            it shall so notify the Company in writing not less than one (1) business day from its receipt
                                            of the original notice of the Equity Financing, and further shall execute all Equity Financing
                                            documents as required and deliver them and the purchase price for such securities and such
                                            other items as are specified to be delivered under such documents to the Company on or prior
                                            to the Equity Financing proposed closing date (or such later date as the Company may agree
                                            in writing). Notwithstanding the foregoing, in the event that such an Equity Financing is
                                            performed as an overnight transaction, the Company shall notify Partner the same in writing
                                            as soon as reasonably practicable, and if Partner wishes to participate in the Equity Financing,
                                            it shall so notify the Company in writing within not less than two (2) hours from its receipt
                                            of the said notice. For the avoidance of doubt, it is hereby clarified that the lack of response
                                            from Partner within the time limitations prescribed in this Section 4.2 shall be deemed as
                                            Partner’s response that it does not wish to participate in such Equity Financing and
                                            waives its rights under this Section 4. Reference
                                            herein to Partner’s Representative means Mr. Barak Avitbul.

 

		4.3.	Notwithstanding
                                            the foregoing, the Right of Participation under this Section 4 shall not apply in respect
                                            of an Equity Financing and
                                            the issuance of Equity Securities by the Company in
                                            connection with issuance of securities (i) to officers, directors, employees or consultants
                                            of the Company pursuant to any compensation agreement, plan or arrangement, (ii) upon the
                                            exercise of any options, warrants or other securities exercisable or convertible into the
                                            Company’s securities, provided such securities are issued and outstanding as of the
                                            date hereof, (iii) for consideration other than cash pursuant to a merger, consolidation,
                                            acquisition, or similar business combination approved by the Company’s board of directors
                                            or (iv) share split, share dividend or
                                            any similar recapitalization.

 

		5.	Confidentiality
                                            and Publicity. Neither party may discuss or disclose any information, or originate any
                                            publicity, news release, or other public announcement, written or oral, whether to the public
                                            press, shareholders, or otherwise, regarding the terms and conditions of this Agreement,
                                            or the performance by either party of its obligations under this Agreement. However, the
                                            parties may discuss, disclose, or originate publicity, news releases, or other public announcements
                                            relating to information which (a) is or becomes generally available to the public other than
                                            as the result of an unauthorized disclosure by either party; (b) becomes available to either
                                            party in a manner that is not in contravention of any applicable laws from a source that
                                            is not bound by a confidential relationship with the other party; or (c) either party reasonably
                                            determines it is appropriate for disclosure under any applicable law or is required to be
                                            disclosed by any law, court order, or other legal process, including, without limitation,
                                            US and/or Israel securities laws.

 

		6.	Irrevocable
                                            Undertaking. Upon the date hereof, the Company and Mr. Avitbul shall enter into irrevocable
                                            undertaking in the form attached as Schedule ‎6 hereto.

 

    8

     

    

 

		7.	Term
                                            and Termination.

 

		7.1.	Term
                                            of Agreement. This Agreement shall commence on the Effective Date and shall be in force
                                            until all obligations of the Parties hereunder are fully satisfied, unless earlier terminated
                                            as set forth herein.

 

		7.2.	Termination.
                                            Notwithstanding the above, this Agreement may be terminated by a Party, as follows: (a) by
                                            the Company, upon seven (7) days prior written notice, if the Partner breaches its obligations
                                            under Sections ‎1.1 or ‎1.2 hereunder, and fails to cure such breach within the notice
                                            period; (b) by the Partner upon seven (7) days prior written notice, if the Company breaches
                                            its obligation under Sections ‎2.1‎2.3, ‎3.1 and ‎3.7 hereunder and fails
                                            to cure such breach within the notice period; (c) immediately upon written notice in the
                                            event that: (i) a receiver is appointed for either Party or its property; (ii) either Party
                                            makes a general assignment for the benefit of its creditors; (iii) either Party commences,
                                            or has commenced against it, proceedings under any bankruptcy, insolvency or debtor’s relief
                                            law, which proceedings are not dismissed within sixty (60) days. The terminating Party shall
                                            be entitled to all the remedies under applicable law.

 

		8.	Binding
                                            Agreement and Assignment. This Agreement shall be binding upon and inure to the benefit
                                            of the parties and their respective successors and permitted assigns. Neither party may assign
                                            any of its rights or obligations under this Agreement to any individual or entity without
                                            the express written consent of the other party. Notwithstanding the foregoing, the Company
                                            may sell, transfer or assign any rights with respect to the Product (whether directly or
                                            through or by any of its subsidiaries) without securing from the assignee an acknowledgement
                                            of the obligations under this Agreement, but only subject to the following provisions: (i)
                                            within five (5) business days following the date of such assignment, the parties shall examine
                                            (a) which amount of Net Eligible Revenues was due and payable to the Partner up to the date
                                            of assignment, in accordance with the agreed forecast of revenues attached hereto as Schedule
                                            ‎8 (the “Planned Revenues”)
                                            and (b) which amount of Net Eligible Revenues was actually received and due by the
                                            Partner until the date of assignment (the “Actual
                                            Revenues”); (ii) the difference
                                            between the Planned Revenues and the Actual Revenues (the “Difference”)
                                            shall be allocated to the remaining future payments of the Planned Revenues (set forth in
                                            Schedule ‎ ‎8), pro rata to such payments,
                                            where a positive Difference shall increase such payments and a negative Difference shall
                                            decrease same (the “Adjusted Payments”); (iii) the Company, at
                                            its sole discretion, shall elect whether to pay the Partner (x) the Adjusted Payments on
                                            their respective dates set forth in Schedule ‎8 or (y) the aggregate outstanding Adjusted
                                            Payments, in one-time payment capitalized at the annual rate of SOFR (Secured
                                            Overnight Financing Rate) known on the assignment date plus [**]%
                                            per annum, which payment shall be made not later than ten (10) business days following the
                                            date of assignment.

 

		9.	Entire
                                            Agreement, Headings, and Modification. This Agreement contains the entire understandings
                                            of the parties with respect to the subject matter herein and supersedes all previous agreements
                                            (oral and written), negotiations, and discussions. The descriptive headings of the sections
                                            of this Agreement are inserted for convenience only and shall not control or affect the meaning
                                            or construction of any provision hereof. Any modifications or amendments to this Agreement
                                            must be in writing and signed by both parties.

 

		10.	Choice
                                            of Law; Jurisdiction. This Agreement shall be construed, governed, interpreted, and applied
                                            in accordance with the laws of the State of Israel, exclusive of its conflicts of law provisions. All
                                            disputes, controversies, differences, or questions arising out of or relating to this Agreement,
                                            or to the validity, interpretation, breach, violation of term thereof, which is not settled
                                            amicably by the Parties, will be finally and solely determined and settled by arbitration
                                            in Israel before a single arbitrator (the “Arbitrator”), in Hebrew language,
                                            and in accordance with the Israeli Arbitration Law, 1968 (for purposes of which this Section
                                            constitutes an arbitration agreement). The identity of the Arbitrator will be agreed upon
                                            between the Parties in writing, or, in case such agreement is not reached within fifteen
                                            (15) days following the request made by any Party to the dispute, by the chairman of the
                                            Israeli Bar Association. The Arbitrator shall be bound by material law but shall not be bound
                                            by the rules of evidence or civil procedure, and shall give written reasons for any decision.
                                            The Arbitrator shall be authorized to render interim awards and partial verdicts.

 

    9

     

    

 

		11.	Waiver.
                                            The waiver by either Party of the breach of any covenant or provision in this Agreement
                                            shall not operate or be construed as a waiver of any subsequent breach by either party.

 

		12.	Severability.
                                            In the event a court of competent jurisdiction declares any term or provision of this
                                            Agreement to be invalid or unenforceable for any reason, this Agreement will remain in full
                                            force and effect, and either: (a) the invalid or unenforceable provision(s) will be modified
                                            to the minimum extent necessary to make such provision(s) valid and enforceable; or (b) if
                                            such a modification is not possible, this Agreement will be interpreted as if such invalid
                                            or unenforceable provision(s) were not a part of this Agreement.

 

		13.	Notices.
                                            All notices and other communications given or made pursuant to this Agreement will be in
                                            writing and will be deemed effectively given: (a) upon personal delivery to the party to
                                            be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal
                                            business hours at the place of the recipient, and if not so confirmed, then on the next business
                                            day, (c) five (5) days after having been sent by registered or certified mail, return receipt
                                            requested, postage prepaid, or (d) two (2) days after deposit with a nationally recognized
                                            overnight courier, specifying next day delivery, with written verification of receipt. All
                                            communications will be sent to the respective parties at their address as set forth above.
                                            Notices by email to the Company shall be addressed to the attention of the CFO, Mr. Shai
                                            Avnit - shai.avnit@safetgroup.com. Notices by email to the Partner shall be addressed to
                                            the attention of Mr. Barak Avitbul [**].

 

		14.	Counterparts.
                                            This Agreement may be executed in any number of counterparts, all of which will constitute
                                            one and the same instrument and will be an original of this Agreement.

 

    10

     

    

 

IN
WITNESS WHEREOF, this Agreement has been executed by the parties hereto through their duly authorized representatives.

 

	Safe-T
    Group Ltd.	 	ORB
    Spring Ltd.
	 	 	 
	/s/
    Shachar Daniel	 	/s/
    Barak Avitbul
	Shachar
    Daniel, Chief Executive Officer	 	Barak
    Avitbul, Chief Executive Officer
	 	 	 
	/s/
    Shai Avnit	 	 
	Shai
    Avnit, Chief Financial Officer	 	 

 

Agreed
and acknowledged:

 

	/s/
    Barak Avitbul	 
	Barak
    Avitbul	 

 

    11

     

    

 

SCHEDULE
1

 

PRODUCTS

 

The
following products are included for purpose of calculating Net Eligible Revenue:

 

	Product
    Name	Approval
    Date
	[**]	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 

 

    12

     

    

 

SCHEDULE
1.2

 

TRANCHES
TIMETABLE

 

[**]

 

SCHEDULE
‎3.4A

 

FORM
OF SERIES A WARRANT

 

SCHEDULE
‎3.4B

 

FORM
OF SERIES B WARRANT

 

SCHEDULE
‎3.4C

 

FORM
OF SERIES B WARRANT

 

SCHEDULE
‎3.4D

 

FORM
OF SERIES B WARRANT

 

SCHEDULE
‎3.8

 

CERTIFICATION
BY MR. AVITBUL

 

[**]

 

SCHEDULE
‎6

 

IRREVOCABLE
UNDERTAKING

 

[**]

 

SCHEDULE
‎8

 

PLANNED
REVENUES 

 

[**]

 

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]